Recent advances in the treatment of homozygous familial hypercholesterolaemia

Current Opinion in Lipidology

Volumn 24, Issue 4, 2013, Pages 288-294

  Marais, Adrian D ^a,c   Blom, Dirk J ^b  

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Antisense oligonucleotides; Homozygous familial hypercholesterolaemia; Microsomal triglyceride transfer protein inhibitors; Plasma cholesterol modifying treatment; Plasmapheresis

Indexed keywords

APOLIPOPROTEIN B100; ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NICOTINIC ACID;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DYSLIPIDEMIA; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE ERYTHEMA; LIPID METABOLISM; LIPID STORAGE; LIPOPROTEIN METABOLISM; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; PATIENT CARE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; DISEASE MANAGEMENT; GENETIC THERAPY; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPID METABOLISM; LIPOPROTEINS; PLASMAPHERESIS;

EID: 84880608435     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32836308bc     Document Type: Review

References (46)

1. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34-47.
2. Hoeg JM, Starzl TE, Brewer HB. Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia. Am J Cardiol 1987; 59:705-707.
3. Zelcer N, Hong C, Boyadjian R, Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009; 325:100-104.
4. Genser B, Silbernagel G, De Backer G, et al. Plant sterols and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J 2012; 33:444-4515.
5. Huff MW, Pollex RL, Hegele RA. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol 2006; 26:2433-2438.
6. Issa JS, Garrido A, Giannini SD, et al. Clinical outcome of patients with familial hypercholesterolemia and coronary artery disease undergoing partial ileal bypass Surgery. Arq Bras Cardiol 2000; 75:54-58.
7. Starzl TE, Chase P, Ahrens EH, et al. Portocaval shunt in patients with familial hypercholesterolemia. Ann Surg 1983; 198:273-283.
8. Marais AD, Naoumova RP, Firth JC, et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 1997; 38:2071-2078.
9. Wetterau JR, Lin MCM, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta 1997; 1345:136-150.
10. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev 2004; 25:49-68.
11. Rubinsztein DC, Raal FJ, Seftel HC, et al. Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. Arterioscler Thromb 1993; 13:1076-1081.
12. Tada H, Kawashiri MA, Ikewaki K, et al. Altered metabolism in low-density lipoprotein and very low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo. Circ Cardiovasc Genet 2012; 5:35-41.
13. Palacio CH, Harring TR, Nguyen NT, et al. Homozygous familial hypercholesterolemia: a case series and a review of the literature. Case Rep Transplant 2011; doi: 10.1155/2011/154908.
14. Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipidlowering therapy. Circulation 2011; 124:2202-2207.
15. Macchiaiolo M, Galiardi MG, Toscano A, et al. Homozygous familial hypercholesterolaemia. Lancet 2012; 379:1330.
16. Morimoto N, Okada K, Okita Y. Successful surgical management for aortic and mitral stenosis in homozygous familial hypercholesterolemia: a case report. Gen Thorac Cardiovasc Surg 2011; 59:491-494.
17. El-Rassi I, Chehab G, Saliba Z, et al. Fatal cardiac atherosclerosis in a child 10 years after liver transplantation: a case report review. J Clin Lipidol 2011; 5:329-332.
18. Schuff-Werner P, Fenger S, Kohlschein P. Role of lipid apheresis in changing times. Clin Res Cardiol Suppl 2012; 7:7-14.
19. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010; 208:317-321.
20. Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler Suppl 2013;14; 14:67-70.
21. Schettler V, Neumann CL, Hulpke-Wette M, et al., German Apheresis Group. Current view: indications for extracorporeal lipid apheresis treatment. Clin Res Cardiol Suppl 2012; 7:15-19.
22. Harada-Shiba M, Arais H, Oikawa S, et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb 2012; 19:1043-1060.
23. Graesdal A, Bogsrud MP, Holven KB, et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol 2012; 6:331-339.
24. Stefanutti C, Morozzi C, Di Giacomo S. New clinical perspectives of hypolipidemic drug therapy in severe hypercholesterolemia. Curr Med Chem 2012; 19:4861-4868.
25. Anedda S, Mura S, Marcello C, Pintus P. HELP LDL-apheresis in two cases of familial hypercholesterolemic pregnant women. Transfus Apher Sci 2011; 44:21-24.
26. Nenseter MS, Narverud I, Graesdal A, et al. Elevated serum MMP-9/TIMP-1 ratio in patients with homozygous familial hypercholesterolemia: effects of LDL-apheresis. Cytokine 2013; 61:194-198.
27. Stefanutti C, Vivenzio A, Di Giacomo S, Ferraro PM. Cytokines profile in serum of homozygous familial hypercholesterolemia is changed by LDL apheresis. Cytokines 2011; 55:245-250.
28. Küçükkartaller T, Yankol Y, Kanmaz T, et al. Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia. Pediatr Transplant 2011; 15:281-284.
29. Maiorana A, Nobili V, Calandra S, et al. Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr Transplant 2011; 15:E25-E29.
30. Giakoustidis A, Cherian TP, Antoniadis N, Giakoustidis D. Combined cardiac surgery and liver transplantation: three decades of worldwide results. J Gastrointestin Liver Dis 2011; 20:415-421.
31. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012; 223:262-268.
32. Raper A, Kolansky DM, Cuchel M. Treatment of familial hypercholesterolemia: is there a need beyond statin therapy? Curr Atheroscler Rep 2012; 14:11-16.
33. Bell DA, Hooper AJ, Watts GF, Burnett JR. Mipomersen and other therapies for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag 2012; 8:651-659.
34. Farnier M, Bruckert E. Severe familial hypercholesterolaemia: current and future management. Arch Cardiovasc Dis 2012; 105:656-665.
35. Parhofer KG. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid 2012; 7:29-38.
36. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012; 33:1142-1149.
37. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:998-1006.
38. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381:40-46.
39. Raal FJ. Lomitapide for homozygous familial hypercholesterolaemia. Lancet 2013; 381:7-8.
40. Pisciotta L, Bellocchio A, Bertolini S. Neutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholestrolemic subjects and its addictive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering plasma. Lipids Health Dis 2012; 11:123.
41. Lin JZ, Martagon AJ, Hsueh WA, et al. Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor. Endocrinology 2012; 153:6136-6144.
42. Temel RE, Brown JM. A new framework for reverse cholesterol transport - biliary contributions to reverse cholesterol transport. World J Gastroenterol 2010; 16:5946-5952.
43. Van Craeyveld E, Jacobs F, Gordts SC, De Geest B. Gene therapy for familial hypercholesterolemia. Curr Pharm Des 2011; 17:2575-2591.
44. Kassim Sh, Li H, Bell P, et al. Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia. Hum Gene Ther 2013; 24:19-26.
45. Fattahi F, Asgari S, Pournasr B, et al. Disease-corrected hepatocyte-like cells from familial hypercholesterolemia-indiced pluripotent stem cells. Mol Biotechnol 2012; DOI.1007/s12033-012-9635-3.
46. Disterer P, Al-Shawi R, Ellmerich S, et al. Exon skipping of hepatic apob premrna with splice-switching oligonucleotides reduces LDL cholesterol in vivo. Mol Ther 2013; doi: 10.1038/mt.2012.264.